J&J gets diabetes drug go-ahead
The US Food and Drug Administration cleared the drug, known as canagliflozin, to treat adults with Type 2 diabetes, the agency said in a statement. It may generate $800m (€622m) in peak sales, Tony Butler, an analyst at Barclays Plc in New York, said.
The treatment, to be sold under the name Invokana, expels sugar in the urine after the kidneys filter it from the blood. The FDA has required J&J to conduct five post-market studies to track possible health risks, including to the heart, bones and pancreas.
